Chris Meyer

Co-founder and COO of @ABLi_Thera. Working day & night to create disease modifying therapies for neurodegenerative disorders. Views expressed here are my own

[Chris Meyer @chmeyer187]

Dave, well said. Parkinson's is where that mindset is needed most. There is still no approved therapy that slows progression.

At ABLi Therapeutics, our c-Abl inhibitor risvodetinib produced the first documented reduction of α-synuclein pathology in patients (Nature Aging, Feb 2026). Our Phase 3 is FDA-aligned and ready to go.

We're looking for pharma partners and investors who see neurodegeneration the way you described. I'd welcome a conversation with your team.

[FierceBiotech @FierceBiotech]

Why a Texas congressman believes Chinese biotechs are 'beating us on our ground game' https://t.co/0FOVXDngIS

[Chris Meyer @chmeyer187]

@Biotech2k1 A few out of hundreds trying to raise money doesn’t count as a bubble. I’m speaking from direct, lived experience. I get your point ….. I just don’t think it’s a bubble. But we shall see what next year brings.

[Chris Meyer @chmeyer187]

@BillAckman An amazing story of love and determination. So grateful that you turned your challenging experience into opportunity for the future. We are in the age where we are can fully understand the complexity of the brain and develop treatments and techniques that will improve lives.

[ABLi Therapeutics @ABLi_Thera]

Our CEO Milton Werner, Ph.D. joined Spencer Knight on The BioShift Podcast to discuss his journey from scientist to CEO, the motivation behind ABLi, & his unwavering mission to develop disease-modifying therapies for #ParkinsonsDisease.

🎧 Listen here: https://t.co/EyjEsoFOfd

[ABLi Therapeutics @ABLi_Thera]

ABLi is advancing the first disease modifying therapy that works inside and outside of the brain and looks forward to sharing more updates from the BASE-PD study, the first to implement alpha-synuclein PET imaging in the brain as an outcome measurement for success.

[ABLi Therapeutics @ABLi_Thera]

At the Needham & Company Conference, CEO Milton Werner shared new data from our completed 201 trial in #ParkinsonsDisease showing that #risvodetinib can reverse the biochemical disease course in PD in just 12 weeks & impacts both #neurodegeneration & #neuroinflammation pathways.

[ABLi Therapeutics @ABLi_Thera]

⏩ Watch the full presentation of our new results here: https://t.co/dxiCA1dAAV

[ABLi Therapeutics @ABLi_Thera]

Hear it straight from our CEO Milton Werner on our groundbreaking approach:
📍 Needham Conference — April 13-16: https://t.co/phLxAlFWBd
📍 World Parkinson's Congress — May 24-27: https://t.co/6vprD62cqT
⚡ Meet the team to hear what motivates our work & follow along for updates.

[ABLi Therapeutics @ABLi_Thera]

ABLi’s #biomarker research has mapped both underlying pathways that drive #ParkinsonsDisease - neuroinflammation and neurodegeneration. #risvodetinib targets both pathways directly. Not just symptoms but the disease itself. That's what a disease-modifying therapy looks like.

[ABLi Therapeutics @ABLi_Thera]

Today on #WorldParkinsonsDay we are highlighting #TheSpark behind our mission.

DYK that Parkinson's disease has no approved therapy that slows or stops progression?
For 200 years of research, that hasn't changed.
We think it's about to. 🧵

[ABLi Therapeutics @ABLi_Thera]

At the @CitizensBank Life Sciences Conference, our CEO Milton Werner, PhD, explains why targeting just one pathway isn’t enough and how #risvodetinib is designed to address both neuronal cell death & neuroinflammation in #ParkinsonsDisease.

🎥 Watch here: https://t.co/vAKUXp1ZmQ

[ABLi Therapeutics @ABLi_Thera]

🧠 At #ADPD2026, CEO Milton Werner, PhD, shared our groundbreaking progress advancing #risvodetinib for #ParkinsonsDisease including new biomarker data that proves risvodetinib is truly modifying human #ParkinsonsDisease. Stay updated: https://t.co/I6eq9Z3bhX

[Chris Meyer @chmeyer187]

I encourage you to take a few minutes to watch this video from @MichaelJFoxOrg on why disease-modifying therapies matter and why so many people living with Parkinson’s are still waiting for options that can meaningfully slow progression.

It’s a powerful reminder that even an incremental slowing of disease could preserve daily function and the moments that bring joy for patients and families alike.

Grateful to the patients, care partners, clinicians, researchers, and advocates driving this forward.

At @ABLi_Thera , we’re working every day with urgency and care to advance real disease modification.

https://t.co/ABUO1VXCmU

[ABLi Therapeutics @ABLi_Thera]

We are excited to announce that ABLi has completed a collaboration agreement with The Michael J. Fox Foundation to include #risvodetinib in the Path to Prevention (P2P) Trial.

Read the press release to learn more: https://t.co/cmBdYB0ykj

[Longevity Technology @LongevityTech]

A new imaging-drug collaboration aims to show whether progression of Parkinson’s disease can be slowed, not just managed.

https://t.co/5lvQQpVDRT

#longevity #parkinsons #neurotech #digitalhealth #biomarkers #realtimedata #medtech #neurology

[ABLi Therapeutics @ABLi_Thera]

#ICYMI last week we announced a collaboration to implement alpha-synuclein PET imaging into our upcoming clinical trials evaluating #risvodetinib as a disease modifying therapy for #ParkinsonsDisease.

Read this #ParkinsonsNewsToday article to learn more: https://t.co/PkqUIkT27P

[ABLi Therapeutics @ABLi_Thera]

Today we are excited to announce a new strategic collaboration with SynuSight Biotech and XingImaging to evaluate alpha-synuclein clearance from the brain in response to #risvodetinib treatment in #ParkinsonsDisease.

Read the press release to learn more: https://t.co/IFoh5rdsIT

[ABLi Therapeutics @ABLi_Thera]

ABLi Therapeutics is headed to San Francisco for the annual @jpmorgan Healthcare Conference. Our CEO, Milton Werner, will share our progress advancing #risvodetinib for treating Parkinson’s disease and what’s next in 2026. Want to learn more? Reach out: https://t.co/JbFcFQlq2a